FDA Schedules Public Hearing on Therapeutic Use of Psychedelic Drugs

The Food and Drug Administration on Monday announced a public hearing on the potential therapeutic use of psychedelic drugs, set for September 14, 2026, and on the same day released its first final guidance for companies running clinical trials of substances such as psilocybin, LSD and MDMA. Together, the two Federal Register notices mark the agency's most concrete steps yet to carry out Executive Order 14401, the April directive that ordered federal health agencies to accelerate research on psychedelic medicine.

The hearing, published under docket FDA-2026-N-7542, will run from 12:30 p.m. to 4:30 p.m. Eastern Time in a hybrid format, with in-person attendance at the agency's White Oak campus in Silver Spring, Maryland. Registration and requests to present are due by August 21, and written comments will be accepted through October 5, 2026.

What the September hearing will cover

The FDA said it wants feedback on four questions that would shape how psychedelic treatments reach patients if any win approval: provider training and credentialing, patient safety, considerations for access, and best practices for collecting and standardizing data. Sub-topics listed in the notice include informed consent for patients facing "the risk of psychological distress or a challenging psychedelic experience," screening for cardiovascular disease, psychosis and suicidality, diversion controls, telehealth, and how insurers might pay for supervised dosing sessions.

The agency drew firm boundaries around the discussion. It is not seeking comment on the merits of any pending application, on scheduling under the Controlled Substances Act, or on legalization, decriminalization or state programs authorizing psychedelic use. FDA panelists from the Center for Drug Evaluation and Research will hear testimony alongside other federal officials, and the agency said it expects requests to present to exceed the time available.

Final rules of the road for trial design

The companion document, "Psychedelic Drugs: Considerations for Clinical Investigations," finalizes a draft that had been pending since June 2023. Its central concern is what the agency calls functional unblinding: because psychedelics produce unmistakable effects, trial participants can usually tell whether they received the drug or a placebo. The guidance says results must be "strongly persuasive and robust across study endpoints" to overcome the biases that problem introduces.

The document also spells out staffing rules for dosing sessions. Each session requires two trained monitors, with the lead being a licensed clinician holding graduate-level psychotherapy training; if that person is not a physician, one must be reachable within 15 minutes. Sponsors studying chronic conditions should follow patients for up to a year to establish durability, and compounds active at the 5-HT2B receptor need heart-valve safety workups. Analysts at Jefferies wrote that the final guidance "suggests the agency remains receptive to helping sponsors succeed."

Building on an April executive order

Both actions trace back to the executive order President Trump signed in April, which directed HHS and the FDA to expand clinical trial participation, data sharing and real-world evidence generation for psychedelic drugs and committed at least $50 million to support state research programs. Since then, the agency has issued national priority vouchers covering psilocybin programs for treatment-resistant depression and major depressive disorder and a methylone program for post-traumatic stress disorder.

The Department of Veterans Affairs and HHS also signed a memorandum of understanding this week to coordinate psychedelic research for veterans' mental health, and the VA said it is involved in more than 20 active trials. Much of that research focuses on veterans with treatment-resistant PTSD and depression, populations for whom existing medications often fall short.

A different posture than 2024

The flurry of activity stands in contrast to the agency's most recent decision on a psychedelic application, when it declined to approve MDMA-assisted therapy for PTSD in August 2024 and asked sponsor Lykos Therapeutics for an additional Phase 3 trial. The rejection turned largely on the same functional unblinding problem the new guidance now addresses head-on.

Whether the friendlier framework produces an approval may be tested soon. Compass Pathways reported positive Phase 3 results for its psilocybin candidate in treatment-resistant depression this month and has said it could complete its submission by the end of the year — a timeline that would make it the first psychedelic application reviewed under the rules published Monday. Psilocybin, LSD and MDMA all remain Schedule I controlled substances, and the FDA emphasized that neither the hearing nor the guidance changes the evidentiary standard any drug must meet for approval.